Related Experiment Videos
Rapid-onset endothelial dysfunction with adriamycin: evidence for a dysfunctional nitric oxide synthase
Damon Duquaine1, Glenn A Hirsch, Anjan Chakrabarti
1Department of Internal Medicine, University of Michigan School of Medicine, Ann Arbor, MI, USA.
Vascular Medicine (London, England)
|October 2, 2003
Summary
Adriamycin (ADR) causes endothelial dysfunction by generating superoxide radicals, leading to reduced nitric oxide (NO) levels. This study shows ADR impairs blood vessel function, potentially explaining cardiovascular risks associated with this chemotherapy.
Area of Science:
- Cardiovascular Research
- Pharmacology
- Biochemistry
Background:
- Adriamycin (ADR) is a chemotherapy drug known to cause cardiovascular complications.
- Its mechanism is thought to involve the generation of oxygen free radicals.
Purpose of the Study:
- To investigate if ADR administration causes endothelial nitric oxide synthase (eNOS)-dependent superoxide generation and acute endothelial dysfunction.
- To assess the impact of ADR on nitric oxide (NO) levels and vascular function in both animal models and human patients.
Main Methods:
- Rabbits received a single dose of ADR, and their vascular responses were measured.
- In vitro studies exposed arterial segments to ADR, measuring superoxide generation via electron spin resonance (ESR).
- Human patients undergoing ADR chemotherapy had brachial artery flow-mediated dilation (FMD) assessed before and after ADR infusion.
Main Results:
- ADR rapidly attenuated agonist-dependent responses in rabbits and markedly reduced brachial artery FMD in patients.
- In vitro, ADR induced superoxide generation in a manner dependent on endothelial cells and likely eNOS.
- Serum nitrite and nitrate levels decreased significantly post-ADR, while markers of endothelial damage remained unchanged.
Conclusions:
- ADR administration leads to rapid depletion of systemic NO and impairs endothelial function.
- Evidence suggests an endothelial origin for radical production, possibly via eNOS or NADPH cytochrome P450 reductase.
- These findings highlight a potential mechanism for ADR-induced cardiovascular complications.